2019年第12次第三人體試驗委員會會議記錄

2019year 12th-C IRB Meeting Minutes

一、日 期 Date(YY/MM/DD): 2019 年 12 月 26 日(星期四)

二、時 間 Time: 12:00-13:48

三、地 點 Location: 福懋大樓 B1 尊榮 B 廳

四、主 席 Chairperson:

張櫻霖(院內、醫療、醫師、男性)

Chang, Ing-Lin(Affiliation with Institution, Medical Personnel (Scientific member), doctor, male)【IRB191210 利益迴避-協同主持人為三親等內之姻親 IRB 191210 Avoiding conflicts of interest- co-PI is the third degree affined relationship】

出席人員 Attendant: (職稱略 omit title)

- 陳彥宇(院內、醫療、醫師、男性) 【熟稔易受傷害族群-中醫醫學生,臨床教師】 Chen, Yen Yu (Affiliation with Institution, Medical Personnel (Scientific member), doctor, male)
- 高峻凱(院內、醫療、醫師、男性) Kao, Jun-Kai(Affiliation with Institution, Medical Personnel (Scientific member), doctor, male)
- 高小玲(院内、醫療、公衛/統計、女性) Kao, Hsiao-Ling(Affiliation with Institution, Medical Personnel (Scientific member), Member of society, female)
- 蔡忠融(院外、醫療、公衛/統計、男性)
 Tsai, Chung-Jung(non-Affiliation with Institution, Medical Personnel (Scientific member),
 Epidemiology/ Statistics, male)
- 洪婉純(院內、非醫療、社工、女性) Hung, Wan-Chun(Affiliation with Institution, Nonmedical Personnel (non-Scientific member), Social Worker, female)
- 陳明鋒(院內、非醫療、法律專業、男性)
 Chen, Ming-Fong (Affiliation with Institution, Nonmedical Personnel (non-Scientific member), Law, male)
- 蔡佩凌(院外、醫療、藥師、女性) Tsai, Pei-Ling(non-Affiliation with Institution, Medical Personnel (Scientific member), Pharmacist, female)
- 劉乃誌(院外、非醫療、社會公正人士、男性) Liu, Nai-Chih(non-Affiliation with Institution, Nonmedical Personnel (Scientific member), Member of society, male)
- 蕭玲玲(院外、非醫療、家庭主婦、女性)

Hsiao, Ling-Ling (non-Affiliation with Institution, Nonmedical Personnel (non-Scientific member), Member of society, female)

■ 吳姿慧(院外、非醫療、家庭主婦、女性)

Wu, Tzu-Hui (non-Affiliation with Institution, Nonmedical Personnel (non-Scientific member), Member of society, female)

| | 人數 | 備註 Remark |
|----------------|---------|--|
| | Persons | |
| 醫療 | 6 | 醫師(3)、藥師(1)、統計(2) |
| Medical | | Doctor (3), Pharmacist (1), Statistics (2) |
| Personnel | | |
| 非醫療 | 5 | 社工(1)、法律(1)、社會公正人士(3) |
| Nonmedical | | Social Worker (1), Law (1), Member of society (3) |
| Personnel | | |
| 科學 | 7 | 醫師(3)、藥師(1)、統計(2)、社會公正人士(1) |
| Scientific | | Doctor (3), Pharmacist (1), Statistics (2), Member of |
| member | | society (1) |
| 非科學 | 4 | 社工(1)、法律(1)、社會公正人士(2) |
| non-Scientific | | Social Worker (1), Law (1), Member of society (2) |
| member | | |
| 男 | 6 | 院内(4)、院外(2) |
| Male | | Affiliation with Institution (4), non-Affiliation with |
| | | Institution (2) |
| 女 | 5 | 院内(2)、院外(3) |
| Female | | Affiliation with Institution (2), non-Affiliation with |
| | | Institution (3) |

備註:① 依據「人體研究法」第七條:審查會應置委員五人以上,包含法律專家及其他社會公正人士;研究機構以外人士應達五分之二以上;任一性別不得低於三分之一。審查會開會時,得邀請研究計畫相關領域專家,或研究對象所屬特定群體之代表列席陳述意見。

Remark: (According to Article 7 of Human Body Research Law, the review board shall comprise of at least 5 board members, including legal experts and other impartial citizens. More than two-fifths of the board members shall be persons not affiliated with the research institution and either of the genders shall not account for less than one-third of the board. Experts in the field related to the study protocol or representatives of the special population in the study shall be invited to attend review board meetings and voice their opinions.

- ② 依據「人體研究倫理審查委員會組織及運作管理辦法」第六條:審查 會召開一般程序審查會議時,其出席委員應包括機構外之非具生物醫 學科學背景委員一人以上。五人以上,不足七人之審查會,應有三分 之二以上之委員出席;七人以上之審查會,應有半數以上之委員出 席,始得開會。出席委員均為單一性別時,不得進行會議。
- ② According to Article 6 of "The Organization and Operation of Human Research Ethics Review Board," attendees of the general board meetings shall include more than 1 board member who is not affiliated with the institution and who does not have biomedical background. For review boards of more than 5 members and less than 7 members, more than two-thirds of the members shall attend the meetings. For review boards of more than 7 members, the meeting shall only start if more than half of the members are present. If all the attendees are of the similar gender, the meeting shall not be conducted.

列席人員 Presenting staff: (職稱略 omit title)

- 葉正吉 (IRB 行政人員) Yeh, Cheng Chi (IRB staff)
- 林巧芸 (IRB 行政人員) Lin, Ciao Yun (IRB staff)
- 洪翠霞 (IRB 行政人員) Hung, Tsui-Hsia (IRB staff)
- 李欣儀 (IRB 行政人員) Li, Hsin-Yi (IRB staff)

請 假 Leave:(職稱略 omit title)

■ 倪渟淵(院内、醫療、醫師、女性)
Ni, Ting-Yuan (Affiliation with Institution, Medical Personnel (Scientific member), doctor, female)

缺 席 Absence: (職稱略 omit title)

記 錄 Recorder: 洪翠霞 Hung, Tsui-Hsia

五、討論議案:

| 主題 | 計畫名稱 | 決議 |
|-----------|---|-------|
| 編號:191210 | 一項隨機分配、開放標記、多中心第二期試驗,評 | 修正後提會 |
| 【新案】 | 估 capmatinib (INC280) 併用 pembrolizumab 相較 | |
| 主持人:林聖皓 | 於單獨使用 pembrolizumab,作為局部晚期或轉移 | |
| | 性 PD-L1 大於等於 50% 非小細胞肺癌第一線治療 | |
| | 的療效及安全性 | |
| 編號:191215 | 以光體積變化描記圖法量測 | 修正後複審 |
| 【新案】 | Reflex-Auricula-Cardiaque 作為中醫眼科耳針臨床技 | |

| 主持人: 陳瑩陵 | 能教學之輔助工具 | |
|-----------|---|------------|
| 編號:190406 | 第二型糖尿病患者的 Semaglutide 心血管結果試驗 | 核准 |
| 【變更案第3次】 | (SOUL) | |
| 主持人:杜思德 | (3001) | |
| 編號:161107 | | 修正後複審 |
| 【期中報告第3次】 | 甲基化 STAT3 標的基因在胃癌之鑒定及臨床應用 | |
| 主持人: 林淑惠 | | |
| 編號:171203 | 合併愛滋病毒與 B 型肝炎病毒感染者使用 | 修正後複審 |
| 【期中報告第2次】 | Elvitegravir/Cobicistat/Emtricitabine/Tenofovir | |
| 主持人:劉尊榮 | Alafenamide (Genvoya) 做為維持治療之療效與副作 | |
| | 用分析之觀察性研究 | |
| 編號:171207 | 探討 P2X7 嘌呤受體、激(月太)釋放(酉每)相關(月 | 修正後複審 |
| 【期中報告第2次】 | 太)(酉每)-5、激(月太)釋放(酉每)相關(月太)(酉 | |
| 主持人:葉靜芳 | 每)-10、轉移相關蛋白 2、鋅拇指蛋白-1、五聚環蛋 | |
| | 白-3 在人類肝癌和腎臟癌病人之關聯性分析 | |
| 編號:181023 | 兩種不同多焦點人工水晶體對於白內障病人術後光 | 修正後複審 |
| 【期中報告第1次】 | | |
| 主持人:張朝凱 | 學品質和視覺品質之比較 | |
| 編號:181207 | | 核准 |
| 【期中報告第1次】 | 肥胖與乳癌微環境:從分子機轉到精準醫療 | |
| 主持人:陳達人 | | |
| 編號:171010 | 一項第 3 期、多中心、雙盲、隨機分配、安慰劑對 | 存查,同意試驗繼續進 |
| 【不遵從事件】 | 照試驗,在罹患先前未治療且帶有 IDH1 突變之急 | 行 |
| 201912-2 | 性骨髓性白血病的 18 歲受試者中,探討 AG-120 | |
| 主持人:賴冠銘 | 併用 Azacitidine 療法 | |
| 編號:161206 | 一項隨機分配、多中心、開放性、第三期臨床試驗, | 通過 |
| 【實地訪視第3次】 | 評估無抗體的 A 型血友病患者接受 Emicizumab | |
| 主持人:沈銘鏡 | 預防性治療,相較於無預防性治療之療效、安全性 | |
| | 和藥物動力學 | |